Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Merit Medical Systems designs, manufactures, and markets medical devices, primarily for interventional radiology, cardiology, and vascular surgery. The company reported record revenues for both the quarter and the nine-month period ended September 30, 2008.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2008 | 9 Months Ended Sep 30, 2008 |
|---|---|---|
| Net Sales | $58,153 | $169,147 |
| Gross Profit | $23,684 | $69,778 |
| Gross Margin | 40.7% | 41.3% |
| Operating Income | $7,169 | $22,782 |
| Net Income | $5,200 | $15,335 |
| Diluted EPS | $0.18 | $0.54 |
| Cash from Operations (9mo) | $19,009 | |
| Cash and Equivalents (Sep 30, 2008) | $31,081 | |
| Working Capital (Sep 30, 2008) | $76,717 | |
| Debt Outstanding | $0 (Lines of credit unused) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% for the quarter and 10% for the nine-month period compared to the same periods in 2007. Growth was driven by increased sales of catheters (Prelude, Mini access, Proguide), custom kits, and stand-alone devices.
- Margin Expansion: Gross margins improved to 40.7% (Q3) and 41.3% (9mo) from 39.1% and 37.9% in the prior year. Improvements were attributed to lower fixed overhead unit costs, production automation, lower unit costs for Mexico-built products, and favorable product mix changes.
- Profitability: Net income rose 21% for the quarter and 41% for the nine-month period year-over-year.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 22% for the quarter. This included approximately $534,000 in insurance deductibles related to Hurricane Ike damage at the Angleton, Texas facility, and $298,000 in write-offs for discontinued product line equipment.
- Acquisitions: The company acquired three catheter platforms from Micrus Endovascular Corporation for $3.0 million (paid $1.5M cash, accrued $1.5M) and made milestone payments to GMA and Milamy Partners for distribution rights.
Guidance, Outlook, and Risks
- Outlook: Management intends to continue developing manufacturing efficiencies and focusing sales efforts on higher-margin products, including new introductions.
- Tax Matters: The effective tax rate for the nine months was 34.2%, higher than the prior year's 33.3%, primarily due to the lapse of the federal R&D tax credit for 2008. Management expects this credit to be retroactively reinstated in the fourth quarter of 2008.
- Foreign Exchange: Approximately 11% of revenues are denominated in Euros and GBP. A stronger Euro/GBP relative to the USD increased revenues by approximately $541,000 in the quarter. The company uses forward contracts to hedge exposure.
- Risks: Key risks include product recalls, liability claims, regulatory approval delays, concentration of revenue among few customers, and potential obsolescence of technology. The company also noted routine legal proceedings with no expected material adverse effect.
- Liquidity: The company maintains a $30 million line of credit with Bank of America and a $1 million line with Zion's First National Bank, both of which were unused as of September 30, 2008.
Investor Verification Checklist
- Hurricane Ike Impact: Verify the final cost of the Angleton facility damage and insurance recovery status beyond the $534,000 deductible recorded in Q3.
- R&D Tax Credit: Confirm the retroactive reinstatement of the 2008 federal R&D tax credit in Q4 filings to assess the impact on the full-year effective tax rate.
- Acquisition Integration: Monitor the integration and revenue contribution of the Micrus catheter platforms and the Kanguru Abdominal Retraction System.
- Inventory Levels: Review inventory turnover given the increase in inventory to $38.4 million and the $2.4 million obsolescence reserve.
- Foreign Currency Exposure: Track the impact of Euro and GBP fluctuations on future margins given the 11% revenue exposure.